Our Purpose

“To Create Cures, Not Treatments”

Make every CLL/MCL patient eligible for safe and effective CAR-T cell therapy. With our first-in-class 5th generation Tandem CAR, we are going to redefine current lymphoma treatment. This will be accomplished by targeting a combination of novel tumor-specific antigens and introducing a novel signaling domain. As a result, our TanCAR confers superior CAR T-cell eradication of CLL cells, sparing healthy cells and limiting cell-therapy related negative effects and consequences.

Our Solution

Immunofusion’s 5^th generation TanCAR encompasses two distant technologies – novel tandem targeting module – TanCLL and an engineered signaling module – ILX-cel, that are solving the major issues of existing CAR-T therapies

ILX-cel technology

With our 5th generation CAR-T therapy, patients can expect durable responses, prolonged remission periods and cure of patients. Our innovative design promotes an enhanced T-cell expansion/persistence and killing capacity, reducing the likelihood of disease relapse and offering patients long-term peace of mind

Every patient will obtain the most specific CAR-T cell product matching their lymphoma antigen repertoire ensuring unprecedented efficacy and response rates

TanCLL technology

By leveraging state-of-the-art engineering, our CAR-T therapy combines very tumor-specific antigen targeting and CAR-T armoring for high potency against high tumor burden (adverse factor for all 2 generation CAR-T cells), minimization harm to healthy tissues and at the same time lowering the possibility of antigen-negative relapses (drawback of all 2 generation CAR-T cells) posing a bold aim of patients cure.

We’ve prioritized safety every step of the way. Our advanced and tumor-specific design mitigates the risk of adverse events commonly associated with traditional CAR-T therapies, such as B-cell aplasia and subsequent infections, offering patients a smoother treatment journey with reduced chances of complications

We’re committed to pushing the boundaries of CAR-T therapy, far beyond our TanCAR main indication. Now we are ready to expand our technology to the autoimmune disease field by precisely targeting only specific and pathogenic B-cells instead of depletion of all B-cells

Unmet medical need in CLL\MCL treatment

CAR-T manufactoring issues, up to (%)

CAR-T treatment failures, up to (%)

News